RO 438857

Drug Profile

RO 438857

Latest Information Update: 05 Feb 2010

Price : $50

At a glance

  • Originator Roche
  • Class Antiplatelets; Small molecules
  • Mechanism of Action Glucokinase stimulants; GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Thrombosis; Type 2 diabetes mellitus

Most Recent Events

  • 10 Jun 2008 Pharmacodynamics data from a clinical trial in patients with Type-2 diabetes mellitus presented at the 68th Annual Scientific Sessions of the American Diabetes Association (ADA-2008)
  • 15 Oct 1998 Discontinued - Preclinical trials for Thrombosis in Switzerland (PO)
  • 02 Feb 1996 An animal study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top